SEC Filing Summary: PerkinElmer, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for PerkinElmer, Inc. (Note: The input metadata references "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). The report covers the quarterly period ended September 30, 2007, and the nine months ended September 30, 2007. PerkinElmer operates in two primary segments: Life and Analytical Sciences (drug discovery, genetic screening, environmental analysis) and Optoelectronics (digital imaging, sensors, specialty lighting).
Key Financial Metrics
Revenue and Profit (Nine Months Ended Sept 30, 2007):
- Sales: $1,275.9 million (up 14% vs. prior year).
- Operating Income: $117.1 million (up 16% vs. prior year).
- Net Income: $79.1 million (up 2% vs. prior year).
- Diluted EPS: $0.65 (vs. $0.61 prior year).
- Gross Margin: 40.1% (flat vs. prior year).
Liquidity and Debt:
- Cash and Cash Equivalents: $160.9 million (down from $191.1 million at year-end 2006).
- Long-term Debt: $246.1 million (up from $151.8 million at year-end 2006).
- Operating Cash Flow: $110.5 million provided by continuing operations (up significantly from $43.2 million prior year, largely due to lower tax payments on divestitures).
- Capital Expenditures: $38.0 million.
Material Changes vs. Prior Period
- Revenue Growth: Driven by organic growth, favorable foreign exchange rates (approx. 3-4% contribution), and acquisitions (approx. 3-5% contribution). Life and Analytical Sciences sales grew 15% YTD; Optoelectronics grew 12% YTD.
- Insurance Claim Gain: A one-time gain of $15.3 million was recorded in Q2 2007 from the settlement of an insurance claim related to a 2005 fire at a Boston facility. This significantly boosted operating income for the nine-month period.
- Restructuring and Lease Charges: Net charges of $7.6 million for the nine months ended Sept 30, 2007. This includes a $4.4 million charge for a Q1 2007 workforce reduction plan and lease costs related to a 2001 divestiture, partially offset by a $1.4 million reversal in Q3.
- Acquisitions: Completed acquisitions of Evotec, Euroscreen, Improvision, and others in 2007, resulting in a $1.5 million in-process research and development (IPR&D) charge.
- Share Repurchases: The company repurchased 7.1 million shares for $176.0 million during the nine months ended Sept 30, 2007.
Guidance, Outlook, and Risks
Recent Developments and Outlook:
- ViaCell Acquisition: On October 1, 2007, PerkinElmer announced a definitive agreement to acquire ViaCell, Inc. for approximately $300 million in cash. The transaction is expected to close in Q4 2007 and will expand offerings in neonatal and prenatal markets. Financing is being sought via an interim credit facility.
- Leadership Succession: Robert F. Friel was named President and COO in August 2007, with plans to become CEO in February 2008. Current CEO Gregory L. Summe will transition to Executive Chairman.
- Decommissioning Costs: The company expects to incur remaining costs of $7.1 million to decommission the fire-damaged Boston facility by the end of fiscal 2008.
Risks and Contingencies:
- Legal Proceedings: Ongoing patent litigation with Enzo Biochem and Amersham Biosciences regarding high-throughput screening technologies. The company believes it has meritorious defenses but cannot estimate potential losses.
- Tax Matters: The company has $14.9 million in accrued tax liabilities (FIN No. 48) expected to be resolved within the next year. U.S. federal returns for 2003-2005 are under examination.
- Environmental: Accrued $4.1 million for environmental remediation at current and former sites.
Investor Verification Checklist
- ViaCell Financing: Verify the terms and closing status of the $300 million ViaCell acquisition and the associated interim credit facility.
- Insurance Settlement Impact: Assess the sustainability of earnings excluding the $15.3 million one-time insurance gain.
- Debt Covenants: Confirm compliance with the amended senior unsecured credit facility covenants, particularly given the increased debt load from the ViaCell financing.
- Legal Exposure: Monitor the status of the Enzo and Amersham patent lawsuits for potential material adverse impacts.
- Segment Performance: Review the specific growth drivers in the Life and Analytical Sciences segment, which accounts for the majority of revenue growth.